Get the Stockscreener App
1.94
9.27%
0.16
After Hours:
1.91
-0.03
-1.55%
Cardiff Oncology Inc stock is traded at $1.94, with a volume of 1.83M.
It is up +9.27% in the last 24 hours and up +13.08% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$1.78
Open:
$1.82
24h Volume:
1.83M
Relative Volume:
2.28
Market Cap:
$132.64M
Revenue:
$593.00K
Net Income/Loss:
$-45.85M
P/E Ratio:
-2.8259
EPS:
-0.6865
Net Cash Flow:
$-37.97M
1W Performance:
+10.51%
1M Performance:
+13.08%
6M Performance:
-16.88%
1Y Performance:
-35.81%
1-Day Range:
$1.81
$2.00
1-Week Range:
$1.68
$2.00
52-Week Range:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.94 | 121.70M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
CRDF Technical Analysis | Trend, Signals & Chart Patterns | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Is Cardiff Oncology (CRDF) 5.1% Undervalued After Q1 2026 Earnin - GuruFocus
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $6 to $10 - Moomoo
Cardiff Oncology (CRDF) Reports Positive Trial Data and Leadersh - GuruFocus
Cardiff Oncology (CRDF) Secures Funding Through 1Q27 - GuruFocus
Cardiff Oncology Q1 net loss narrows as operating expenses fall - TradingView
Cardiff Oncology earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology: Q1 Earnings Snapshot - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) details Q1 2026 loss and Phase 3 plans - Stock Titan
FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) posts Q1 loss, warns on cash and details onvansertib data - Stock Titan
Cardiff Oncology, Inc.Common Stock (NQ: CRDF - FinancialContent
CRDF Stock Price, Quote & Chart | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
Cardiff Oncology (CRDF) to Release Earnings on Thursday - MarketBeat
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - GlobeNewswire
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):